Compared with previously published results in this field, our study provided a novel personalized treatment regimen for the particular immune HCC subtype based on integrating multiomics information of potential tumor antigen genes, which may benefit clinical practice in future [25, 26, 49]. This evidence concerns the gene LINC01194 and hepatocellular carcinoma.